Title: Efficacy and safety of glecaprevir and pibrentasvir in Japanese patients with hepatitis C
virus infection aged 75 years or older
Version: 1 Date: 11 Mar 2022
Reviewer's report:
This study is interesting since patients #75 years old are underrepresented in most studies. I have
some comments to the authors:
What is the HCV prevalence in #75 years old in Japan?
What is the HCV prevalence in #75 years old in these centers? How many patients #75 years
old were not treated? Why were these patients not treated? I would be interesting to see these
results since patients #75 years old were not frequently treated due to their age, but they have
a high SVR rate and might benefit from treatment.
16 patients dropped out treatment, only 1 due to AEs. Why did the other 15 dropped out?
Why patients with HCV genotypes 4-6 were excluded?
Please change NS5A resistance-associated variants (RAVs) for NS5A resistance-associated
substitutions (RASs)
Title: Efficacy and safety of glecaprevir and pibrentasvir in Japanese patients with hepatitis C
virus infection aged 75 years or older
Version: 1 Date: 11 Mar 2022
Reviewer's report:
This study is interesting since patients #75 years old are underrepresented in most studies. I have
some comments to the authors:
What is the HCV prevalence in #75 years old in Japan?
What is the HCV prevalence in #75 years old in these centers? How many patients #75 years
old were not treated? Why were these patients not treated? I would be interesting to see these
results since patients #75 years old were not frequently treated due to their age, but they have
a high SVR rate and might benefit from treatment.
16 patients dropped out treatment, only 1 due to AEs. Why did the other 15 dropped out?
Why patients with HCV genotypes 4-6 were excluded?
Please change NS5A resistance-associated variants (RAVs) for NS5A resistance-associated
substitutions (RASs)
Please review this paper.
user
Title: Efficacy and safety of glecaprevir and pibrentasvir in Japanese patients with hepatitis C
virus infection aged 75 years or older
Version: 1 Date: 11 Mar 2022
Reviewer's report:
This study is interesting since patients #75 years old are underrepresented in most studies. I have
some comments to the authors:
What is the HCV prevalence in #75 years old in Japan?
What is the HCV prevalence in #75 years old in these centers? How many patients #75 years
old were not treated? Why were these patients not treated? I would be interesting to see these
results since patients #75 years old were not frequently treated due to their age, but they have
a high SVR rate and might benefit from treatment.
16 patients dropped out treatment, only 1 due to AEs. Why did the other 15 dropped out?
Why patients with HCV genotypes 4-6 were excluded?
Please change NS5A resistance-associated variants (RAVs) for NS5A resistance-associated
substitutions (RASs)
assistant